Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-018-0422-z
Abstract: Allogeneic hematopoietic cell transplant (alloHCT) represents a significant therapeutic approach for patients diagnosed with lymphoid malignancies (LM). However, relapse remains a major cause of treatment failure. In this scenario, a number of strategies have been… read more here.
Keywords: dli; allohct; allogeneic hematopoietic; donor ... See more keywords
Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139615
Abstract: BACKGROUND: In a previous study we have shown that CD19-directed chimeric antigen receptor (CAR)-T cells do not appear to be inferior to alloHCT when used as standard cellular immunotherapy (CI) for patients with multiply r/r… read more here.
Keywords: allohct; research funding; car; easix ... See more keywords
HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194874
Abstract: Introduction The prognosis of patients with acute myeloid leukemia (AML) is influenced by multiple factors, including patient-related characteristics, disease specifics, and treatment response. Measurable residual disease (MRD) monitoring during therapy and follow-up offers prognostic information… read more here.
Keywords: relapse; mfc; mrd; hla expression ... See more keywords
Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-201944
Abstract: Background: B-cell non-Hodgkin lymphomas (B-NHL) encompass a heterogeneous group of malignancies with diverse prognosis. Some patients (pts) achieve long-term remission with standard therapies, but many experience relapse or refractory (R/R) disease. Recently, bispecific antibodies (BsAb)… read more here.
Keywords: disease; therapy; stem cell; bsab ... See more keywords